Qube Research & Technologies LTD Lyell Immunopharma, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.39 - $2.35 $11,815 - $19,975	8,500 New	8,500 $16,000
Q1 2022 May 09, 2022	SELL	$5.05 - $7.7 $56,903 - $86,763	-11,268 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$7.13 - $15.19 $80,340 - $171,160	11,268 New	11,268 $87,000
Q3 2021 Nov 12, 2021	SELL	$11.0 - $17.95 $500,555 - $816,814	-45,505 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$15.99 - $16.89 $727,624 - $768,579	45,505 New	45,505 $739,000

122

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $273M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.